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Abstract
Background—The Beers list of potentially inappropriate medications (PIMs) provides a key 
indicator of medication prescribing quality. The criteria were updated in 2012, adding new drugs 
and assessing evidence strength.
Objectives—To use the most recently available population-based data to estimate PIM 
prevalence under the 2012 update and to provide a benchmark from which to measure future 
changes.
Design and Setting—Retrospective cohort study using nationally representative data from the 
2006–2010 Medical Expenditure Panel Survey (MEPS).
Participants—Community-dwelling sample of US older adults (n = 18,475).
Measurements—We operationalized the updated Beers criteria, generating a “broad” PIM 
definition that incorporated form, route or dose restrictions where clearly specified and a 
“qualified” definition that applied specific exceptions where mentioned in the rationale associated 
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with each drug category. Bivariate analyses described PIM prevalence, comparing the two 
operational definitions, and examined time trends.
Results—Among older adults with prescription medications, 42.6% had at least one medication 
fill that met the broad definition, with non-steroidal anti-inflammatory drugs (NSAIDs) having the 
highest (10.9%) prevalence. The rate declined from 45.5% in 2006–2007 to 40.8% in 2009–2010. 
The categories with the largest absolute decline were NSAIDs, selected sulfonylureas, and 
estrogens. PIM prevalence was 30.7% using the qualified definition.
Conclusion—Despite the overall high use of PIMs, there has been a decline observed in recent 
years. Future studies should test the effect of educational and clinical interventions on changes in 
PIM use and patient outcomes. The current study results can aid in targeting these interventions.
Keywords
inappropriate; Beers criteria; older adults; medication; MEPS
INTRODUCTION
The Beers list of potentially inappropriate medications (PIMs) is a key indicator of 
medication prescribing quality, as well as an important educational tool for clinicians. 
Initially developed in 1991 with a focus on medication use in nursing home residents,1 the 
list was updated and expanded to include all geriatric care settings in 1997 and again in 
2003.2,3 In 2012, an expert panel was convened in collaboration with the American 
Geriatrics Society to update the Beers criteria.4 The panel was charged with both updating 
the Beers list and rating the quality of evidence which supported the panel’s 
recommendations. To accomplish this, the panel systematically reviewed the literature, 
entertained public comment and graded the published evidence during an open period, per 
the Institute of Medicine standards. This approach ensured transparency and rigor. A 
modified Delphi method was used to achieve consensus on the panel’s recommendations.
PIMs continue to be prescribed to older adults, despite evidence of poor outcomes and 
adverse events.5–9 Prevalence of PIMs has been assessed in a variety of studies, in different 
settings and subpopulations, including several U.S. population-based. For example, 
estimates by Zhan et al.,10 based on the 1996 Medical Expenditure Panel Survey (MEPS), 
indicate that over one-fifth of community-dwelling adults aged 65 years and over received at 
least one of 33 PIMs. PIM exposure was more common in older adults with poor health and 
a larger number of prescriptions. Trends from 1987 to 1996 indicated a reduction in PIM use 
for some drug groups. Decreased PIM exposures, and a higher risk of PIM exposures 
associated with poor health was confirmed in a study by Stuart et al.11 using the 1995 and 
1999 Medicare Current Beneficiary Survey. A more recent study by Zhang et al.12 used the 
2007 MEPS and operationalized the same 33 PIM recommendations from prior studies, 
found a dramatic decline in PIM exposure for older adults from 21.3% in 1996 to 13.8% in 
2007.
With ongoing changes in medications available in the market, changing indications, and a 
heightened emphasis on medication safety, PIM use is a moving target, and estimates need 
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to be updated regularly. Prior estimates of PIM exposure reflect both earlier time periods 
and earlier versions of the Beers criteria. Furthermore, most prior estimates of PIM exposure 
selected drugs from the Beers list that should be avoided in all or most cases, but did not 
apply specific qualifying criteria such as dose, duration, and reason for use. To help fill the 
gap in the literature, and to provide a benchmark from which to observe future changes, we 
used the most recently available MEPS data to update PIM prevalence estimates that 
incorporate recent changes to the Beers criteria. Our study illustrates how operationalizing 
additional details of the Beers panel’s recommendations alters the estimates of PIM 
prevalence, and provides a more clinically relevant estimate of PIMs. We also use the new 
system of evidence ratings in the Beers criteria to distinguish those PIM exposures 
supported by stronger evidence.
METHODS
Data and Cohort
We used data from the 2006–2010 MEPS, an on-going overlapping panel survey sponsored 
by the Agency for Healthcare Research and Quality (AHRQ) that collects detailed and 
nationally representative information on health care utilization and expenditures, insurance 
coverage, sources of payment, health status, and socio-demographic variables for the U.S. 
civilian, non-institutionalized population.13,14 Each year a new panel of households is 
sampled and interviewed in five survey rounds over two-and-a-half years to obtain annual 
data reflecting a two year reference period. In each interview round, the MEPS collects 
information concerning new prescription fills. Respondents commonly use medicine bottles 
and receipts when providing this information, hence respondents tend to report chronic 
condition medication use accurately.15 Additional details about medications, including 
quantity or days supplied, are obtained from dispensing pharmacies. The MEPS Prescribed 
Medicines files are linked to the Multum Lexicon database, a product of Cerner Multum, 
Inc., which facilitated identification of relevant drugs. The study also used the MEPS 
Condition files and Full-Year Consolidated files, which contain information on individuals’ 
demographic, socio-economic and health characteristics. We limited our sample to adults 
aged 65 years and above.
Criteria Selection
The 2012 update of the Beers’ criteria identified 38categories of drugs that should be 
avoided by older adults, as well as criteria specific to older adults with selected chronic 
conditions, and a smaller set of criteria associated with medications that should be used with 
caution. We focused on the first set of criteria, as they are applied most broadly, and 
scrutinized the criteria to determine which ones could be operationalized with greatest 
reliability using self-reported prescription drug and medical condition data reported in the 
MEPS. We selected 36 of the 38 categories, excluding insulin dosed on a sliding scale, as 
the MEPS did not provide a mechanism to distinguish a fixed from a flexible dosing 
schedule. We also excluded mineral oil, which we expected to be purchased over-the-
counter, and thus, poorly documented within the MEPS.
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Operational Definitions of PIM Use
Generating the operational definitions of PIM use involved a three-step process. In Step 1 
we used the updated Beers’ criteria to identify relevant medication names or therapeutic 
classes and the specific restrictions or exceptions related to dose, route, duration, and 
medical condition, as well as the ratings of evidence quality and recommendation strength. 
We merged this information onto the prescription medication files by drug name (including 
combination products) or therapeutic class so that each medication fill record had the 
relevant criteria to assess whether it qualified as a PIM. In Step 2 we used the data elements 
in the MEPS medication file to compute the parameters (e.g. dose), needed to assess whether 
the fill met the operational definitions for PIM use. The MEPS Prescribed Medication files 
include information on drug name, therapeutic class, dose form, route of administration, 
strength, quantity, and reasons for use (medical condition for which the drug was used). 
Medication fills from 2009 and 2010 also included days supplied, which we used to 
calculate daily quantity (fill quantity/days supplied). We used the information on daily 
quantity from fills in 2009–2010 to logically impute days supplied values for each drug/
quantity combination in the 2006–2008 data. Information on quantity, strength and days 
supplied was used to calculate daily dose (quantity × strength/days). Finally, days supplied 
for each drug were summed across fills for each person to get annual days supplied, which 
was used to measure therapy duration. The reasons for use were based on self-report and 
coded to International Classification of Diseases, 9th revision, clinical modification (ICD-9-
CM). We searched the medication fills for specific conditions mentioned in the Beers 
criteria. In sensitivity analyses, we linked and applied information about conditions of 
interest reported for each respondent but that were not reported to be the reason for using a 
specific drug. This broader group of conditions may have been reported as the reason for 
using other healthcare services, or because they caused lost work/school or bed days. 
Detailed information about the operational definitions for each drug category is provided in 
Appendix Table 1.
To develop an indicator that a fill met the criteria for a PIM (Step 3), we compared 
information from the Beers criteria (Step 1) to the medication and person-level information 
on each medication record developed during Step 2. We developed two operational 
definitions. A “broad” definition that assigned PIM status based on use of a specified drug, 
applying only those criteria related to form, route or dose restrictions where clearly 
specified. A “qualified” definition applied selected exceptions mentioned in the rationale 
associated with each drug category. These exceptions usually related to requirements for a 
minimum duration or therapy, or the presence of a medical condition, making the qualified 
definition more restrictive. Person-level PIM exposure measures were generated by 
summing the medication fill level PIM measures within each of the 36 drug categories, and 
then generating an indicator of PIM use that cut across the 36 categories.
Analytic Approach
We quantified the number and proportion of prescription medication fills that met the 
definition for PIM use, and the number and proportion of older adults with PIM use overall 
and by drug category. To characterize the difference between the two estimates, we 
measured the proportion of individuals whose PIM status was affected by duration and 
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condition restrictions. We used sampling weights to generate nationally representative, 
average annual estimates overall for 2006–2010. To assess changes in prevalence over time, 
we compared the person-level estimates for the periods 2006–2007 and 2009–2010. 
Estimated standard errors and t-tests of the significance of changes over time accounted for 
the complex design of the MEPS. Analyses were conducted using SAS version 9.2 (Cary, 
NC) and Stata12 (College Station, TX).
RESULTS
The study cohort included 18,475 person-years, accounting for an annual average of 39.58 
million older adults, and 35.93 million older adults with at least one prescription medication. 
Over half (52.1%, S.E. 0.81%) were aged 65–74 years of age, four-fifths were white non-
Hispanic, and 57% (S.E. 0.41%) were female. Detailed information about the characteristics 
of our older adult sample is provided in Appendix Table 2.
Table 1 presents PIM prevalence estimates. Among older adults with prescription 
medication use, 15.3 million, or 42.6% had at least one prescription medication fill that met 
the broad definition for a PIM (left side of table), accounting for 106.0 million PIM fills. 
The prevalence of PIM use by drug category ranged from a negligible quantity (for example, 
chloral hydrate or ergot mesylates) to a high of 10.9% for non-steroidal anti-inflammatory 
drugs (NSAIDs) and 9.3% for benzodiazepines. These drug categories affected 25.7% and 
21.7%, respectively, of older adults with PIM fills. The average number of prescription fills 
per person that met the broad definition for a PIM ranged from a low of 2.6 for 
nitrofurantoin to a high of 6.4 for selected sulfonylureas and tricyclic antidepressants.
The overall prevalence using the qualified definition was 30.7% of older adults with drug 
use. The most prevalent individual categories continued to include NSAIDs, although the 
rate dropped to 4.7%, and selected sulfonylureas were used by 4.1%. The proportion with 
potentially inappropriate benzodiazepine use was much lower under the qualified definition 
at 0.9% of older adult medication users.
Only 9.2% of individual prescription fills could be classified as PIMs using the broad 
definition, with 6.6% under the qualified definition. Tables describing the distribution by 
drug category are provided in Appendix Table 3.
Figure 1 presents information about the distribution of additional criteria that were met 
under the qualified definition. Among older adults with any PIM under the qualified 
definition, 6.8% had a PIM that met specific dose criteria, while 27.7% had a PIM that met 
duration criteria and 19.5% had a PIM that met restrictions based on reasons for use. Nearly 
two-thirds (63.1%) had at least one fill for a drug that should always be avoided.
Figure 2 reports the distribution of adults by the quality of evidence used to characterize 
PIM status. Using the broad definition, over half (22% of 42.6%) of adults with a PIM had 
at least one medication for which the evidence quality was deemed to be high. When the 
qualified definition was applied, that proportion was slightly less than half (14.0% of 
30.7%). We found that almost all adults with PIMs had at least one drug category where the 
recommendation was considered to be strong (data not shown).
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Table 2 shows trends in the proportion of persons with PIM fills using the broad definition, 
comparing the periods from 2006–2007 to 2009–2010. Overall the rate declined from 45.5% 
in 2006–2007 to 40.8% in 2009–2010, representing a 10.3% decrease from the baseline 
(p<0.01). The categories with the largest absolute decline were NSAIDs, selected 
sulfonylureas, and estrogens, while use of skeletal muscle relaxants increased during this 
period. Parallel results using the qualified definition are provided as Appendix Table 4.
DISCUSSION
PIM use has been examined over the past three decades using previously published Beers 
criteria, in different settings and subpopulations, and in both the U.S. and 
internationally.4,10–12 Given the changing landscape of available drugs, it is important to 
present updated information about the prevalence of PIM exposure. This is the first study to 
use nationally representative data for the U.S. community-based population to estimate 
prevalence of PIMs using the 2012 update to the Beers criteria. In this study we developed 
and applied two operational definitions, broad and qualified, to capture PIM use. Since the 
updated criteria included clinical caveats that are often important but hard to clearly define 
with administrative data, our approach is innovative and reveals important new information 
for research, education and practice. The most compelling finding shows that a high 
percentage (42%) of older adults received PIMs, but that a portion of them were used in 
cases where the duration was not particularly long, for patients who lacked specific medical 
conditions identified as problematic, or who had diagnoses for which use was justified. Even 
with these qualifications in the definition, almost one third (30.7%) of community-dwelling 
older adults were prescribed drugs, some of which are known to be associated with falls, 
delirium, declines in cognitive and physical functioning and other potentially serious health 
outcomes.5,6,16 While the proportion of older adults with PIM use is large, these 
prescriptions make up a much smaller proportion of total prescription fills, suggesting that 
most prescribing is not problematic with respect to the dimensions captured by the Beers 
criteria. The analysis does not address adherence to guidelines nor cost of chosen therapy, 
dimensions that may also be relevant as quality and/or value indicators.
The updated 2012 American Geriatrics Society Beers Criteria continues to highlight the use 
of PIMs in older adults. We applied the updated criteria to the 2006–2010 MEPS, which was 
the most recent population-based data available when we conducted our study. These data 
pre-date the new guidelines, hence, they do not reflect potential changes in prescribing that 
may result from their dissemination. However, the evidence base used to update the criteria 
was developed over time, with some of the information available to clinicians during the 
study period. In an environment with evolving availability of both new and old drugs, and 
evidence on their effectiveness and safety, this study provides a useful snapshot and an 
important benchmark to assess the impact of the updated criteria over time.
Our analysis suggests that PIM use is decreasing, yet with the addition of new medication 
categories such as non-benzodiazepine sedatives, continued intervention and surveillance 
are needed.4 Furthermore, PIM use has been operationalized as a marker of quality 
prescribing through various metrics and indicators.17–19 Therefore, it is helpful to target key 
drug categories that have the highest prevalence in this study, namely first generation 
Davidoff et al. Page 6













antihistamines, antispasmodics, nonselective alpha1 blockers, non-benzodiazepine 
hypnotics, estrogens, selected sulfonylureas, NSAIDs and skeletal-muscle relaxants. 
Benzodiazepine use was also highly prevalent using the broad definition, although much less 
common when applying the qualified definition. Despite the continued prevalence in some 
categories, it is encouraging to note that the use of agents such as selected sulfonylureas, and 
digoxin, which have limited efficacy as well as increased adverse effects in older adults, 
appear to be declining.
Our estimates of PIM exposure are similar to estimates from selected subgroups of 
community-based older adults enrolled in managed care organizations (40.7%)6 or receiving 
home care (38%),20 yet substantially higher than those of other general community-based 
population estimates, for example the estimated 13.8% of older adults with PIM use in 
2007.12The study by Zhang et al. applied the same criteria published in an earlier study by 
Zhan et al.10to permit comparison of trends over time. But while this approach may 
document discontinuation of older drugs, it does notincorporate newly available drugs, or 
drugs for which there is new evidence of harm, and will under-estimate the extent of 
problematic drug prescribing. Another key difference is that other studies only 
operationalized the subset of criteria where the drug was to be avoided in all cases. Our 
results indicate that among all adults with PIMs, only 63% of older adults had used PIMs 
that should be avoided universally.
There are limitations to this analysis. Some of the Beers’ criteria could not be fully 
implemented, for example, the MEPS lacks information on the exact timing of medication 
use, so it was not possible to assess concurrent medication use or the timing of medication 
use relative to condition diagnosis. The MEPS drug use data may be subject to under-
reporting. A recent comparison between drug use reported in the MEPS by Medicare 
beneficiaries, compared with Part D claims suggested that the MEPS underreports 
medication use for acute conditions, but to a lesser extent for chronic use.21 Underreporting, 
therefore, is likely to affect our results for nitrofurantoin, but should be less important for the 
majority of other PIMs, which are primarily used to treat chronic conditions. Subsequent 
improvements to procedures for editing drug quantity in the MEPS were applied to these 
data, and are expected to reduce underreporting.15,22 An additional limitation is that the 
reason for use of each drug was based upon self-report. Older adults taking many 
medications, especially off-label, may not be aware of the correct indication. As a result, 
certain diagnoses may be under-reported as the reason for using a drug. For example, 
antipsychotics are contraindicated for treatment of behavioral problems of dementia. We 
observed very few prescription records where the specific ICD-9 code was consistent with 
that criterion. We expanded our search to include dementia more broadly (without requiring 
the behavioral problems), but still found relatively few prescriptions reported as treatment 
related to dementia. We finally considered antipsychotic use among older adults with a 
diagnosis of dementia related to non-drug utilization or disability. As a result there is a large 
difference between PIM prevalence estimates using the broad definition (that did not require 
a diagnosis of dementia) and the qualified definition (that required the dementia diagnosis) 
associated with antipsychotics. We consider these to be upper and lower bound estimates, 
where the true estimate lies is unclear.
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Despite these caveats, this study has several important strengths including the large sample 
size and transparent methods for determining PIM use with the AGS updated Beers criteria. 
This is also the first study to operationalize the clinical definition of PIMS in both a broad 
and qualified manner. This study has clear practice implications and the results illustrate that 
interventions to decrease PIM use are still greatly needed. Several interventions have been 
found to decrease PIM use if done before the point of ordering.23 Several studies have used 
interruptive alerts when PIMs are prescribed to recommend alternative medications or non-
drug approaches,24 reduced dose and frequency, or no medication.25,26 These types of alerts 
are most effective as they require an action from the provider or prescriber of the PIM 
before proceeding.
PIM exposure is a key element of quality. Because prescription drug availability changes 
over time, it is important to continually update the criteria used and add new drugs or 
eliminate drugs that are no longer on the market. In a related study, we examine 
characteristics of older adults who are more likely to experience PIMs, as well as selected 
characteristics of providers, and the association of PIM receipt with other dimensions of 
quality. Future studies should test interventions to decrease PIM use and evaluate the impact 
on clinical and patient outcomes. To have the largest return on investment, interventions to 
reduce PIMs should also focus on the most common PIMs such as NSAIDs and short-acting 
benzodiazepines. Ongoing studies utilizing the updated criteria are important to advancing 
the quality initiative for the prevention of adverse medication events in older adults.
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Source: Medical Expenditure Panel Survey, Household Component, Consolidated files, 
2006–2010.
Note: Individuals may have potentially inappropriate medication use (PIMs) in more than 
one category.
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Source: Medical Expenditure Panel Survey, Household Component, Consolidated files, 
2006–2010.
Note: Individuals with multiple potentially inappropriate medications (PIMs) are categorized 
according the PIM with the highest level of evidence.
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Appendix Table 3
Potentially Inappropriate Prescription Medication Fills Among Older Adults, by Detailed Categories, 2006–
2010
Broad Definition Qualified Definition
PIM fills as a percentage of: PIM fills as a percentage of:
PIM categories All Drug Purchases All PIM Fills All Drug Purchases All PIM Fills
  All PIM fills 9.2% 100.0% 6.6% 100.0%
  Anticholinergics
First generation antihistamines 0.3% 3.5% 0.3% 4.7%
Antiparkinson 0.0% 0.3% 0.0% 0.4%
Antispasmodics 0.3% 3.4% 0.3% 4.8%
Antithrombotics
Dipyridamole rse rse 0.0% rse
Ticlopidine rse rse 0.0% rse
Anti-infective
Nitrofurantoin 0.1% 1.2% 0.1% 1.2%
Cardiovascular
Alpha1 blockers 0.7% 7.7% 0.6% 9.3%
Alpha agonists 0.4% 4.6% 0.4% 6.3%
Antiarrhythmics 0.5% 5.0% 0.2% 2.5%
Disopyramide rse rse rse rse
Dronedarone rse rse rse rse
Digoxin 0.3% 3.6% 0.3% 5.0%
Nifedipine, immediate release 0.0% 0.3% 0.0% 0.4%
Spironolactone 0.1% 0.8% 0.0% rse
Central Nervous System
Tricyclic antidepressants 0.5% 5.0% 0.5% 6.9%
Antipsychotics 0.3% 3.6% 0.0% 0.6%
Thioridazine, Mesoridazine rse rse rse rse
Barbiturates 0.1% 0.7% 0.1% 0.9%
Benzodiazepines (all) 1.6% 17.7% 0.2% 3.0%
    Short acting 1.2% 12.6% 0.1% 1.8%
    Long acting 0.5% 5.1% 0.1% 1.1%
Chloral hydrate 0.0% 0.0% 0.0% 0.0%
Meprobamate rse rse rse rse
Non-benzodiazepine hypnotics 0.5% 5.3% 0.4% 5.9%
Ergot mesylates 0.0% 0.0% 0.0% 0.0%
Endocrine
Androgens 0.0% 0.5% 0.0% 0.4%
Dessicated thyroid 0.1% 1.3% 0.1% 1.8%
Estrogens with or without progestins 0.6% 6.3% 0.6% 8.8%
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Broad Definition Qualified Definition
PIM fills as a percentage of: PIM fills as a percentage of:
PIM categories All Drug Purchases All PIM Fills All Drug Purchases All PIM Fills
Growth hormone rse rse 0.0% rse
Megestrol 0.0% 0.4% 0.0% 0.5%
Sulfonylureas 0.8% 8.8% 0.8% 12.3%
Gastrointestinal
  Metoclopramide 0.2% 1.9% 0.2% 2.6%
Trimethobenzamide rse rse 0.0% rse
Pain
Meperidine rse rse 0.0% rse
Non-COX-selective NSAIDs 1.4% 14.7% 1.0% 15.3%
Indomethacine, Ketorolac 0.1% 0.6% 0.1% 0.9%
Pentazocine rse rse 0.0% rse
Skeletal muscle relaxants 0.3% 3.6% 0.3% 5.1%
Source: Medical Expenditure Panel Survey Household Component, 2006–2010
Notes:
ns = insufficient sample to support reliable estimate; rse = relative standard error > 0.3.
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